The Gabapentin Market is gaining momentum as healthcare providers address the growing burden of chronic pain and neurological disorders. Gabapentin's established role in neuropathic pain management and adjunctive seizure treatment continues to support demand across hospitals, clinics, and pharmacy networks.

Dosage-form diversification remains an important feature of the industry. Capsules, tablets, and oral solutions allow manufacturers to serve different patient requirements, while extended-release formulations are attracting attention because of their potential to support convenient dosing and treatment adherence.

Another important factor is the expansion of pharmaceutical access in emerging markets. Asia-Pacific is projected to experience comparatively strong growth, supported by improving healthcare infrastructure, greater access to medicines, and increasing pharmaceutical production capabilities.

At the same time, manufacturers face challenges associated with generic price competition, regulatory oversight, and changing treatment preferences. Continued investment in manufacturing quality, supply-chain reliability, formulation innovation, and market-specific regulatory strategies will be important for maintaining competitiveness through the forecast period.